Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder
This study plas to investigate the feasibility and efficacy of open-label repeated intravenous administration of ketamine and scopolamine combined in this population of severely depressed, treatment-resistant patients. The results from this study could lead to the development of new strategies for the treatment of patients with TRD.
Details
Background reports show ketamine infusions produce acute reductions in depression and suicidal ideation; scopolamine also shows significant antidepressant effects sustained over time.
Randomized, parallel-design study comparing three arms (ketamine+placebo; scopolamine+placebo; ketamine+scopolamine). Treatments given twice weekly for three weeks (six sessions); follow-up assessments every two weeks for three months.